India's second largest pharma company by market cap Cipla is likely to report a profit after tax of Rs 307 crore in the October-December quarter of FY12, a massive growth of 32% as compared to Rs 232.7 crore in a year ago quarter.
EBITDA too is seen moving up by 35.5% to Rs 431 crore from Rs 318 crore year-on-year.
Operating profit margin is expected to be at 24% in the quarter ended December FY12 versus 20.5% in the corresponding quarter of last fiscal and 24.6% in the previous quarter.
Revenues are likely to go up by 14.2% to Rs 1,774 crore from Rs 1,554 crore YoY.
On quarter-on-quarter basis, revenues and profit after tax are expected to be flat.
Watch out for:
- Exports growth to be led by pick up in Indore SEZ, API & currency depreciation
- Average INR/USD rate for Cipla was Rs 51.12
Discover the latest Business News, Sensex, and Nifty updates. Obtain Personal Finance insights, tax queries, and expert opinions on Moneycontrol or download the Moneycontrol App to stay updated!
